FDA Scientific Capacity Inadequate; New Device Technology At Risk
This article was originally published in The Gray Sheet
CDRH is not equipped to understand the science behind many cutting-edge device technologies, says a Nov. 29 report from the Subcommittee on Science and Technology, an ad hoc panel of the FDA Science Board
You may also be interested in...
Medical countermeasures expert Luciana Borio moves to chief scientist role; Hamburg offers preview of the leadership approaches of Stephen Ostroff and Robert Califf.
A subcommittee is evaluating progress the agency has made in regulatory science since the 2007 report, “FDA Science and Mission at Risk,” was issued, while identifying future needs.
GAO reports on transparency of federal agencies. FDA Science Board to meet in February. More regulatory news.